| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SI2-HF2H6 | Human | FITC-Labeled Human Siglec-2 / CD22 Protein, His Tag |  |
|
|
| SI2-H525a | Human | Human Siglec-2 / CD22 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| SI2-R52Ha | Rhesus macaque | Rhesus macaque Siglec-2 / CD22 Protein, His Tag |  |
|
|
| SI2-M52Ha | Mouse | Mouse Siglec-2 / CD22 Protein, His Tag |  |
|
|
| SI2-H82F8 | Human | Biotinylated Human Siglec-2 / CD22 Protein, Fc,Avitag™ |  |
|
|
| CD2-H52H8 | Human | Human Siglec-2 / CD22 Protein, His Tag |  |
|
|
| SI2-H5228 | Human | Human Siglec-2 / CD22 (176-687) Protein, His Tag |  |
|
|
293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) (QC tested).
Anti-Human CD22 MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human Siglec-2 (176-687), His Tag (Cat. No. SI2-H5228) with an affinity constant of 11.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Moxetumomab pasudotox | CAT-8015; GCR-8015; HA-22 | Approved | AstraZeneca | LUMOXITI | fda | ASTRAZENECA AB | 2018-09-13 | Hairy cell leukemia | Details | |
| Inotuzumab Ozogamicin | CMC-544; PF-5208773; WAY-207294,CMC544,PF5208773,WAY207294 | Approved | Pfizer, UCB | inotuzumab ozogamicin | ema | Pfizer Europe MA EEIG | 2017-06-28 | Acute lymphoblastic leukaemia (ALL) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CD22-CART | Phase Ⅰ | Shanghai Hrain Biotechnology | Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma | Details | |
| Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase Ⅰ | Hrain Biotechnology | Lymphoblastic leukaemia | Details | |
| AUTO-3 | AUTO-3,AUTO3 | Phase Ⅱ | University College London, Autolus | B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) | Details |
| Anti-CD22 CAR-T cell therapy (No. 307 Hospital) | Phase Ⅱ | No 307 Hospital of the Chinese People’s Liberation Army | Acute lymphoblastic leukaemia (ALL) | Details | |
| SM-03 | SM-03; SM-06 | Phase Ⅲ | Lonn Ryonn Pharma, SinoMab Bioscience Ltd | Rheumatoid arthritis (RA) | Details |
| Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) | LCAR-L10D | Phase Ⅰ | Second Affiliated Hospital of Xi'an Jiaotong University, Nanjing Legend Biotech | Diffuse large B cell lymphoma | Details |
| JCAR-018 | JCAR-018 | Phase Ⅰ | National Cancer Institute, Opus Bio, Juno Therapeutics | Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas | Details |
| CD19 and CD22 targeted CAR-T cell therapy (Chongqing Xinqiao Hospital) | Phase Ⅰ | Chongqing Xinqiao Hospital | B-cell lymphoma | Details | |
| CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase Ⅰ | Zhejiang University | Lymphoid Hematological Malignancies | Details | |
| RD-102 | RD-102 | Phase Ⅰ | Nanjing IASO Biotherapeutics | Lymphoblastic leukaemia, Diffuse large B cell lymphoma | Details |
| BAY-1862864 | BAY-1862864 | Phase Ⅰ | Bayer | Non-Hodgkin's lymphoma (NHL) | Details |
| Epratuzumab | AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2,AMG412,CDP3194,IMMU103,IMMU1903,IMMUhLL2 | Phase Ⅲ | Immunomedics, UCB | Sjoegren's syndrome, Systemic lupus erythematosus, Acute lymphoblastic leukaemia (ALL) | Details |
| GTB-1550 | DT-2219ARL; DT-2219; IND-100780; OXS-1550 | Phase Ⅱ | University of Minnesota, Oxis International, GT Biopharma | B-cell lymphoma, Leukemia | Details |
| Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase Ⅱ | M.D. Anderson Cancer Center | Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) | Details | |
| Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase Ⅰ | University of Texas Southwestern Medical Center, Galileo Research | B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) | Details | |
| Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) | Phase Ⅱ | General Hospital of the People's Liberation Army | B-cell lymphoma, Leukemia | Details | |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase Ⅱ | Shenzhen Geno-Immune Medical Institute | B-cell malignancies | Details |
| Epratuzumab I-131 | Phase Ⅱ | Immunomedics, Repligen | Non-Hodgkin's lymphoma (NHL) | Details | |
| UCART-22 | UCART-22 | Phase Ⅰ | Cellectis | Acute lymphoblastic leukaemia (ALL) | Details |
| Pinatuzumab vedotin | DCDT-2980S; FCU-2703; RG-7593; RO-5541072; RO-5541072-000; ACD22-VCMMAE | Phase Ⅱ | Genentech | Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) | Details |
| CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) | Phase Ⅰ | PersonGen Biomedicine | B-cell lymphoma | Details | |
| Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase Ⅰ | Seattle Children's Hospital | Acute lymphoblastic leukaemia (ALL) | Details | |
| Anti-CD22-CAR T cell therapy (Kecellitics Biotech) | Phase Ⅱ | Kecellitics Biotech Company Ltd | Leukemia, Lymphoma | Details | |
| Anti-CD22 CAR T cell therapy (Shanghai GeneChem) | Phase Ⅰ | Shanghai GeneChem | Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas | Details | |
| Bectumomab | Phase Ⅲ | Immunomedics | Non-Hodgkin's lymphoma (NHL) | Details | |
| CART22-cells | CART22-cells | Phase Ⅰ | University of Pennsylvania, Novartis | B-cell lymphoma, Leukemia | Details |
| Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase Ⅰ | Shanghai Jiaotong University | Acute lymphoblastic leukaemia (ALL) | Details | |
| Chimeric antigen receptor T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine) | Phase Ⅱ | Shanghai Unicar-Therapy Bio-medicine Technology | Non-Hodgkin's lymphoma (NHL) | Details | |
| Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) | Phase Ⅰ | Wuhan Bio-Raid Biotechnology | B-cell lymphoma, Multiple myeloma (MM) | Details | |
| Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase Ⅰ | Stanford University | B-cell lymphoma | Details | |
| Epratuzumab Y-90 | 90Y-DOTA-hLL2; 90Y-hLL2; hCD22-Y-90; IMMU-102 | Phase Ⅱ | Immunomedics, Nantes University Hospital | Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) | Details |
| Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) | Phase Ⅰ | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | Acute lymphoblastic leukaemia (ALL) | Details | |
| Anti-CD22 monoclonal antibody-toxin conjugate (Galileo Research/the University of Texas) | IMTOX-22 | Phase Ⅰ | University of Texas Southwestern Medical Center, Royal Free and University College Medical School, Cancer Research Technology, National Institutes of Health, Galileo Research, Abiogen Pharma | Non-Hodgkin B-cell lymphomas | Details |
| CAT-3888 | CAT-3888; BL-22 | Phase Ⅱ | Cambridge Antibody Technology, National Institutes of Health, MedImmune | Lymphoblastic leukaemia, Chronic lymphocytic leukemia (CLL), Hairy cell leukemia, Non-Hodgkin's lymphoma (NHL) | Details |
| RFB4-SMPT-dgA | RFB4-SMPT-dgA; IgG-RFB4-SMPT-dgA; NSC639179 | Phase Ⅰ | National Cancer Institute, University of Texas Southwestern Medical Center | B-cell lymphoma | Details |
| Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase Ⅱ | General Hospital of the People's Liberation Army | Leukemia, Lymphoma | Details | |
| TRPH-222 | TRPH-222; CAT-02-106; CD22-4AP | Phase Ⅰ | Catalent, Triphase Accelerator | B-cell lymphoma | Details |
| Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) | Phase Ⅱ | iCarTAB Biomed | B-cell lymphoma | Details | |
| Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) | Phase Ⅱ | Yake Biotechnology, The First Affiliated Hospital of Zhejiang University School of Medicine, Beijing Boren Hospital | Acute lymphoblastic leukaemia (ALL) | Details |
This web search service is supported by Google Inc.
A-Z